Opportunities in Evidence Generation for Tumor-agnostic Targeted Therapies to Better Support Health Technology Assessments in Europe

Tumor-agnostic therapies are among the most complex cases evaluated by health technology assessment (HTA) bodies and obtaining full approval and reimbursement of these drugs can be difficult for sponsors. Learn more now about how to expand the use of real-world evidence (RWE) to generate meaningful comparative evidence to support HTA decisions.

Learn more about:

• The challenges in determining reimbursement
• Identifying opportunities: The entrectinib NTRK+ case study
• Lessons learned
• Key takeaways from the entrectinib case study
• Recommendations for progress in providing access to tumor agnostic treatments